234
Participants
Start Date
October 31, 2009
Primary Completion Date
October 31, 2010
Study Completion Date
August 31, 2011
Peramivir
300 mg twice daily
Peramivir
600 mg once daily
Dothan
Mobile
Jonesboro
Little Rock
Fountain Valley
Harbor City
La Mesa
Long Beach
Los Angeles
Modesto
Oceanside
Orange
Palo Alto
Sacramento
San Diego
San Francisco
San Jose
Denver
Wheat Ridge
Washington D.C.
Brandon
Fort Lauderdale
Gainsville
Ocoee
Orlando
West Palm Beach
Columbus
Decatur
Honolulu
Idaho Falls
Chicago
Rock Island
Springfield
Indianapolis
South Bend
Topeka
Hazard
Natchitoches
Shreveport
Baltimore
Boston
Detroit
Royal Oak
Troy
Minneapolis
St Louis
Butte
Omaha
Englewood
Hackensack
Neptune City
New Brunswick
Somers Point
Albuquerque
Albany
Brooklyn
Buffalo
Jamaica
New York
The Bronx
Valhalla
Akron
Cleveland
Lima
Toledo
Portland
Philadelphia
Providence
Charleston
Sioux Falls
Houston
San Antonio
Tomball
Salt Lake City
Norfolk
Salem
Bellevue
Seattle
Milwaukee
Brisbane
Cairns
Southport
Clayton
Melbourne
Parkville
Kelowna
Winnipeg
Hamilton
Kingston
Ottawa
Toronto
Chicoutimi
Montreal
Sainte-Foy
Sherbrooke
Trois-Rivières
Saskatoon
Edmonton
Aguascalientes
Guadalajara
Zapopan
Distrito Federal
Monterrey
San Luis Potosí City
Durango
Auckland
Christchurch
Hamilton
Tauranga
San Juan
Lead Sponsor
Department of Health and Human Services
FED
BioCryst Pharmaceuticals
INDUSTRY